hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06298747, orgStudyIdInfo id: Cervical root PRF, briefTitle: Ultrasound-guided Selective Cervical Root Pulsed Radiofrequency Therapy in Patients With Cervical Radicular Pain, acronym: pulsedrf, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2023-07-01, completionDateStruct date: 2023-07-02, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Diskapi Teaching and Research Hospital, class: OTHER, descriptionModule briefSummary: Chronic cervical pain is a common disorder with a prevalence of approximately 35% in adults. Cervical radicular pain is defined as radiating pain in the upper limb caused by compression or inflammation of the nerve roots ascending from the intervertebral foramen to the spinal cord, due to disc herniation or spinal stenosis. C7 and C6 are the two most commonly affected nerve roots. Various treatment modalities are available, including oral medications, physiotherapy, and epidural steroid injections. However, chronic and persistent pain that develops as a result of some patients not responding to these treatments. Ultrasound-guided selective cervical nerve root block and pulsed radiofrequency are interventional treatments used in patients with radicular cervical pain unresponsive to conservative treatments. Pulsed radiofrequency (PRF) treatment of peripheral nerves may provide long-term pain relief in patients with short-term pain relief with a local anesthetic block. Studies have shown the effectiveness of PRF therapy applied to selective cervical nerve roots in relieving cervical radicular pain., conditionsModule conditions: Cervical Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 45, type: ACTUAL, armsInterventionsModule interventions name: Selective cervical nerve root pulsed radiofrequency, outcomesModule primaryOutcomes measure: VAS, secondaryOutcomes measure: Neck Disability Index (NDI), secondaryOutcomes measure: Douleur Neuropathique 4 Questions (DN4), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Etlik City Hospital, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06298734, orgStudyIdInfo id: 23-712, briefTitle: Exercise and Diet Interventions During Immunotherapy in Melanoma Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Dana-Farber Cancer Institute, class: OTHER, collaborators name: World Cancer Research Fund International, descriptionModule briefSummary: The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy.The names of the groups in this research study are:* High-Intensity Exercise (EX)* High-fiber Diet (DT)* Combined High-Intensity Exercise and High-Fiber Diet (COMB)* Attention Control (AC), conditionsModule conditions: Melanoma (Skin), conditions: Skin Cancer, conditions: Advanced Melanoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Exercise Program, interventions name: Diet Program, outcomesModule primaryOutcomes measure: Change in Gut Microbiome Diversity, secondaryOutcomes measure: Change in Systemic Immune Function, secondaryOutcomes measure: Change in Cardiopulmonary Fitness, secondaryOutcomes measure: Change in Short Physical Performance Battery (SPPB), secondaryOutcomes measure: Change in Percent Body Fat, secondaryOutcomes measure: Change in Lean mass, secondaryOutcomes measure: Change in Hip circumference, secondaryOutcomes measure: Change in Waist circumference, secondaryOutcomes measure: Change in Health-Related Quality of life (EORTC-QLQ C30), secondaryOutcomes measure: Change in MDASI-Immunotherapy Questionnaire Score, secondaryOutcomes measure: Change in Anxiety (HADS), secondaryOutcomes measure: Change in Depression (HADS), secondaryOutcomes measure: Change in Sleep Quality (PSQI), secondaryOutcomes measure: Proportion of Participants Completing the Exercise Intervention Sessions, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dana-Farber Cancer Institute, city: Boston, state: Massachusetts, zip: 02215, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06298721, orgStudyIdInfo id: 23-885, briefTitle: Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, collaborators name: American Association of Hip and Knee Surgeons, descriptionModule briefSummary: This study is a randomized controlled trial to assess whether the implementation of a TKA Personalized Outcome Prediction Tool to set expectation, in addition to targeted interventions to address patients with poor baseline mental health and poor physical function, improves satisfaction at 1-year (when compared to standard of care)., conditionsModule conditions: Knee Osteoarthritis, conditions: Knee Arthropathy, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Personalized outcome prediction tool + targeted interventions, interventions name: Standard of Care TKA, outcomesModule primaryOutcomes measure: Satisfaction at 1 year, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cleveland Clinic Foundation, status: RECRUITING, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Shujaa T Khan, MD, role: CONTACT, phone: 419-965-8274, email: khans34@ccf.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06298708, orgStudyIdInfo id: PED-2566-0634, briefTitle: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents, acronym: HAV-RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Chiang Mai University, class: OTHER, collaborators name: Faculty of Medicine, Chiang Mai University, descriptionModule briefSummary: Hepatitis A virus (HAV) vaccine is an effective strategy to prevent natural HAV infection. In Thailand, there are 2 types of HAV vaccine available, including inactivated HAV vaccine and live-attenuated HAV vaccine. This study aims to compare the immunogenicity and safety of inactivated and lived-attenuated HAV vaccine among Thai healthy children and adolescents age 18 months to 18 years., conditionsModule conditions: HAV, conditions: Hepatitis A, conditions: Hep A, conditions: Vaccine-Preventable Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Mevac-A vaccine, interventions name: Havrix 720 Junior, outcomesModule primaryOutcomes measure: Anti-HAV immunoglobulin G (IgG) seroconversion rate, secondaryOutcomes measure: Geometric mean concentration (GMC) of anti-HAV IgG level, eligibilityModule sex: ALL, minimumAge: 18 Months, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06298682, orgStudyIdInfo id: CCM1421, briefTitle: Characterization of Exosomes Platelets-released, acronym: EXOPLT, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-07-08, primaryCompletionDateStruct date: 2026-07-07, completionDateStruct date: 2027-07-07, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Centro Cardiologico Monzino, class: OTHER, collaborators name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, descriptionModule briefSummary: Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited., conditionsModule conditions: Platelet Thrombus, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 175, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Characterization of exosomes released by activated platelet by Nanoparticle Tracking Analysis (NTA) and proteoma analysis, primaryOutcomes measure: Characterization of exosomes released by activated platelet and exposed to platelet inhibitors by NTA and proteoma analysis, secondaryOutcomes measure: Platelet exosome profile emerged by NTA and proteoma analysis will be related with the "biographical" and "anthropometric" data of the subjects., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, status: RECRUITING, city: Milan, country: Italy, contacts name: Daniele Prati, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06298669, orgStudyIdInfo id: 10652, briefTitle: Biventricular Versus Right Ventricular Pacing, statusModule overallStatus: SUSPENDED, startDateStruct date: 2023-08-09, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Indiana University, class: OTHER, descriptionModule briefSummary: The study is a randomized, single-blind crossover prospective study in which investigators will determine the clinical outcomes of cardiac resynchronization therapy (CRT) pacing modalities in patients with left ventricular assist devices (LVAD). Only patients are blinded. This is a small-scale study from which future larger scale randomized controls can be performed. The primary endpoint will be the effect of BiV and RV pacing setting on the 6-minute walk test., conditionsModule conditions: Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Biventricular Pacing, interventions name: Right Ventricular Pacing, outcomesModule primaryOutcomes measure: 6 Minute Walk Test Performance, secondaryOutcomes measure: Serum NT-PRO-BNP, secondaryOutcomes measure: EQ-5D-3L, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Indiana University Health Methodist Hospital, city: Indianapolis, state: Indiana, zip: 46202, country: United States, geoPoint lat: 39.76838, lon: -86.15804, hasResults: False
protocolSection identificationModule nctId: NCT06298656, orgStudyIdInfo id: ILBS-ACLF-17, briefTitle: Acute hemodynamiC Response To Carvedilol Predicts Survival in ACLF Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2026-02-28, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Institute of Liver and Biliary Sciences, India, class: OTHER, descriptionModule briefSummary: Clinically significant portal hypertension (CSPH) is defined as HVPG \>10 mmHg. Patients with CSPH are at risk of developing esophageal varices and clinical decompensation (variceal bleeding, ascites, jaundice, encephalopathy), which mark the transition from compensated stage to a stage of the disease (decompensated) associated with higher mortality (1). HVPG is calculated by subtracting the free hepatic venous pressure (FHVP), a measure of systemic pressure, from the wedged hepatic venous pressure (WHVP), a measure of hepatic sinusoidal pressure. HVPG is surrogate marker in many clinical applications such as gold standard test to evaluate presence and severity of portal hypertension (PHT) diagnosis, risk stratification, monitoring of the patients on beta blockers (2). Non selective beta-blockers like propranolol and carvedilol are indicated in adults for primary and secondary prophylaxis of variceal hemorrhage. Acute hemodynamic response to intravenous propranolol with HVPG values coming down to \<12 mm Hg or reduction to \>20% from baseline have been shown to be associated with reduced long term risk of variceal bleed. Hence we are planning the current work to study the Acute hemodynamiC response To Carvedilol predicts survival in ACLF patients - "ACT - C ACLF study, conditionsModule conditions: Acute-On-Chronic Liver Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Predictive value of acute HVPG change by carvedilol for 28 day transplant free survival in patients of ACLF, secondaryOutcomes measure: Complications [PHT related bleed, AKI, infections, HE, Hypotension, Cardiac side effect] within 90 days, secondaryOutcomes measure: Transplant-free survival rate at 90 days, secondaryOutcomes measure: Correlation with evolution of AARC score by 2 week, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute of Liver & Biliary Sciences (ILBS), city: New Delhi, state: Delhi, zip: 110070, country: India, contacts name: Garvit Mundra, MD, role: CONTACT, phone: 01146300000, email: garvitmundrailbs@gmail.com, geoPoint lat: 28.63576, lon: 77.22445, hasResults: False
protocolSection identificationModule nctId: NCT06298630, orgStudyIdInfo id: 2022-LTF-BRL-101, briefTitle: Long-term Follow-up Study of BRL-101 for TDT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12-08, primaryCompletionDateStruct date: 2038-08-20, completionDateStruct date: 2038-10-15, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Bioray Laboratories, class: INDUSTRY, collaborators name: First Affiliated Hospital of Guangxi Medical University, collaborators name: Xiangya Hospital of Central South University, collaborators name: Chinese Academy of Medical Sciences, collaborators name: Nanfang Hospital, Southern Medical University, collaborators name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, collaborators name: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, collaborators name: Shenzhen Children 's Hospital, descriptionModule briefSummary: Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects., conditionsModule conditions: Thalassemia, Beta, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Assessments, outcomesModule primaryOutcomes measure: Incidence of hematologic malignancies, primaryOutcomes measure: Frequency, grade, and relationship of SAEs, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Nanfang Hospital, Southern Medical University, city: Guangzhou, state: Guangdong, zip: 510006, country: China, contacts name: Xiaoqin Feng, phD, role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, locations facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, city: Guangzhou, state: Guangdong, zip: 510006, country: China, contacts name: Jianpei Fang, phD, role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, locations facility: Shenzhen Children 's Hospital, city: Shenzhen, state: Guangdong, zip: 510006, country: China, contacts name: Sixi Liu, phD, role: CONTACT, geoPoint lat: 22.54554, lon: 114.0683, locations facility: No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital, city: Nanning, state: Guangxi, zip: 530021, country: China, contacts name: Xinhua Zhang, phD, role: CONTACT, geoPoint lat: 22.81667, lon: 108.31667, locations facility: Xiangya Hospital of Central South University, city: Changsha, state: Hunan, zip: 510510, country: China, contacts name: Bin Fu, PhD, role: CONTACT, geoPoint lat: 28.19874, lon: 112.97087, locations facility: Tianjin Institute of Hematology, city: Tianjin, state: Tianjin, zip: 300000, country: China, contacts name: Jun shi, PhD, role: CONTACT, geoPoint lat: 39.14222, lon: 117.17667, locations facility: The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY, city: Guangxi, zip: 530021, country: China, contacts name: Yongrong Lai, PhD, role: CONTACT, hasResults: False
protocolSection identificationModule nctId: NCT06298617, orgStudyIdInfo id: RC 27.1.2024, briefTitle: Systemic Inflammatory Indices as a Non-invasive Grading Modality for Endometriosis, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-07-30, completionDateStruct date: 2023-12-25, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Benha University, class: OTHER, descriptionModule briefSummary: Endometriosis (EMs) is one of the commonest chronic inflammatory disorder affecting women and is characterized by the presence and growth of endometrial-like glandular epithelial and stromal cells outside the uterus leading to multiple clinical symptoms affecting patients quality of life and fertility with high recurrence rate . The systemic immune inflammatory index (SII) and systemic inflammatory response index (SIRI) are documented as prognostic serum biomarker in many kinds of cancer and for the need and outcomes of adjuvant therapies for various cancers ., conditionsModule conditions: Endometriosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 88, type: ACTUAL, armsInterventionsModule interventions name: Diagnostic laparoscopy, interventions name: Full Blood Count (FBC), outcomesModule primaryOutcomes measure: Indices' ability to predict EM stage, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Benha University, city: Banhā, state: Al Qalyobia, zip: 13511, country: Egypt, geoPoint lat: 30.45906, lon: 31.17858, hasResults: False
protocolSection identificationModule nctId: NCT06298591, orgStudyIdInfo id: atrophic scar treatment, briefTitle: The Efficacy of Combination Therapy in Atrophic Scars, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2027-03-15, completionDateStruct date: 2027-03-15, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: There are more than 100 million patients who develop scar formation caused by various factors, such as post-inflammatory acne and trauma (1). They often have physical, aesthetic, psychological, and social barriers. Scar tissue is naturally a stage of wound healing. Abnormal wound healing produces a spectrum of scar tissue types such as atrophic, hypertrophic, and keloid scars (2).Atrophic scars are dermal depressions, which are commonly caused by the destruction of collagen following inflammatory process. This permanent disfiguring sequelae correlates with the duration of pathology, severity of lesion, and delay in therapy (3).Treatment of atrophic acne scars remains a therapeutic challenge, yet there is no standard option as the most effective treatment (4). A range of possible options has been investigated including surgical techniques (subcision, non-ablative laser treatment, resurfacing techniques (ablative laser treatment, dermabrasion), and injection or dermal fillers or fat, and a combination of two or more modalities (5).Ultrasound is a unique non-invasive and non-radiating medical imaging tool in the investigation of dermatological diseases by providing detailed anatomic and physiologic data of skin lesions and deeper soft tissue changes. Lesion size in three dimensions-lengths, width, and depth, morphology, the detailed anatomic information provided by sonography is useful to assessment of effect of different types of treatment modality to improve atrophic scar and avoid invasive assessment tools as punch biopsy for histopathological examination (6), conditionsModule conditions: Atrophic Scar, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: co2 laser, outcomesModule primaryOutcomes measure: change of dermal thickness in sonar and Vancouver scale, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 70 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False